To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pemoline has some advantages over other stimulants in that it does not reduce the appetite or cause dry mouth.
Hepatotoxicity and discontinuation
In some patients Pemoline is suspected of causing hepatotoxicity, so regular liver tests are performed on those treated with it. Since receiving FDA approval in 1975, it has been linked with 21 cases of liver failure, of which 13 resulted in liver replacement or death. In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline due to pressure from certain public advocacy groups, including Public Citizen. The patient support group "Narcolepsy Network" tried to persuade the FDA not to ban it, on the grounds that some patients find all other treatments ineffective or to have debilitating side effects. The medication was used by an estimated 10,000 Americans afflicted with narcolepsy. A more potent analogue of pemoline, 4-methylaminorex has appeared as a black market drug with abuse potential similar to methamphetamine.
In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pemoline". A list of authors is available in Wikipedia.|